% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • robertvince robertvince Jul 16, 2012 7:45 AM Flag

    Alnylam Pharma reports positive ALN-TTR02 clinical data

    :00AM Alnylam Pharma reports positive ALN-TTR02 clinical data, with robust knockdown of serum transthyretin of up to 94% after single dose (ALNY) 12.52 : Co announces the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis. Results from this study show that administration of ALN-TTR02 leads to robust knockdown of serum TTR protein levels of up to 94%; the overall results were highly significant. Suppression of TTR, the disease-causing protein in ATTR, was found to be rapid, dose dependent, durable, and specific after just a single dose. Co recently reported that it has initiated a Phase II study of ALN-TTR02 in patients with ATTR and has guided that its goal is to start a pivotal trial in 2013.

105.25+0.49(+0.47%)Nov 25 4:00 PMEST